RecruitingPhase 1NCT06912295
Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of HL-1186 in Healthy Participants
Sponsor
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Enrollment
76 participants
Start Date
Mar 21, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This single-center, randomized, double-blind, placebo-controlled, two-part study is designed to assess the safety, tolerability and PK of oral HL-1186 Tablet in healthy participants.
Eligibility
Min Age: 18 YearsMax Age: 45 Years
Inclusion Criteria4
- Healthy participants, males and females.
- Between the ages of 18 and 45 years old (inclusive).
- Weighs no less than 50 kg (for males) or 45 kg (for females) and body mass index (BMI) within 19.0 to 26.0 kg/m2 (inclusive).
- During the screening period, vital signs, physical examination, blood routine, blood biochemistry, coagulation function, urine routine, virology examination, chest X-ray, and pregnancy blood test (female) were examined, and the results did not show abnormalities or abnormalities without clinical significance.
Exclusion Criteria6
- Females who are pregnant or breastfeeding; females/males who are prepared for having children.
- History or presence of neurological, cardiovascular, renal, hepatic, gastrointestinal, respiratory, hematological, endocrine, or osteoarticular disorders, or any laboratory abnormalities that pose a potential danger to constitute a risk when taking the study intervention or interfere with the interpretation of data.
- Active infectious diseases which need anti-infection treatment.
- Significant surgery within three months and not fully recovered per investigator's judgments.
- Significant allergies per investigator's judgments, e.g., food allergies, allergies, or atopic reactions to any components of the investigational drug or placebo, asthma attacks, etc.
- Immunosuppressive diseases, e.g., immunodeficiency, etc.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGHL-1186
HL-1186 tablet for oral administration.
DRUGHL-1186 placebo
HL-1186 placebo tablet for oral administration.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06912295
Related Trials
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
NCT070136432 locations
Location- and Frequency-Dependent Effects of Thalamic Temporal Interference Stimulation During Sleep
NCT074982701 location
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
NCT075112053 locations
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults
NCT075135711 location
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
NCT075390901 location